Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain 2-Year Results From the IN.PACT Global Study

Show full item record



Permalink

http://hdl.handle.net/10138/300440

Citation

IN.PACT Global Study Investigators & Venermo , M 2018 , ' Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain 2-Year Results From the IN.PACT Global Study ' , JACC: Cardiovascular Interventions , vol. 11 , no. 10 , pp. 945-953 . https://doi.org/10.1016/j.jcin.2018.02.019

Title: Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain 2-Year Results From the IN.PACT Global Study
Author: IN.PACT Global Study Investigators; Venermo, Maarit
Contributor: University of Helsinki, Verisuonikirurgian yksikkö
Date: 2018-05-28
Language: eng
Number of pages: 9
Belongs to series: JACC: Cardiovascular Interventions
ISSN: 1936-8798
URI: http://hdl.handle.net/10138/300440
Abstract: OBJECTIVES The IN. PACT Global Study is the largest prospective, multicenter, independently adjudicated trial to evaluate a paclitaxel drug-coated balloon in patients with lifestyle-limiting claudication and/or ischemic rest pain due to atherosclerotic disease of the femoropopliteal artery and includes complex lesions beyond what are typically included in randomized controlled trials. BACKGROUND Randomized controlled trials have demonstrated the safety and efficacy of drug-coated balloons for the treatment of Trans-Atlantic Inter-Society Consensus Document II A and B lesions, but there is a need for large-scale prospective studies to evaluate a broader range of lesions. METHODS The IN. PACT Global Study enrolled 1,535 subjects, and 1,406 (1,773 lesions) were included in the pre-defined clinical cohort analysis. Freedom from clinically driven target lesion revascularization was evaluated at 24 months. The safety composite endpoint was freedom from device-and procedure-related death through 30 days and freedom from target limb major amputation and clinically driven target vessel revascularization within 24 months. RESULTS Mean lesion length was 12.1 cm, 35.5% were total occlusions, and 18.0% had in-stent restenosis. Freedom from clinically driven target lesion revascularization at 24 months was 83.3%, the composite safety endpoint was met in 81.7%, the 2-year all-cause mortality rate was 7.0%, and the major target limb amputation rate was 0.7%. Increased lesion length and the presence of de novo in-stent restenosis or coronary artery disease were associated with increased risk for clinically driven target lesion revascularization by 24 months. CONCLUSIONS This real-world study of femoropopliteal artery disease treatment with drug-coated balloons confirmed positive findings reported from more strictly designed randomized controlled trials and showed that outcomes are durable in this population up to 2 years after treatment. (c) 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Subject: angioplasty
drug-coated balloon
femoropopliteal artery
peripheral artery disease
target lesion revascularization
PERIPHERAL ARTERY-DISEASE
SUPERFICIAL FEMORAL-ARTERY
RANDOMIZED-TRIAL
ELUTING BALLOON
SFA-LONG
PACLITAXEL
REGISTRY
RESTENOSIS
ANGIOPLASTY
REVASCULARIZATION
3121 General medicine, internal medicine and other clinical medicine
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S1936879818305636_main.pdf 751.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record